327 related articles for article (PubMed ID: 26869290)
1. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
[TBL] [Abstract][Full Text] [Related]
2. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
[TBL] [Abstract][Full Text] [Related]
3. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.
Mizuno S; Hanamura I; Ota A; Karnan S; Narita T; Ri M; Mizutani M; Goto M; Gotou M; Tsunekawa N; Shikami M; Iida S; Hosokawa Y; Miwa H; Ueda R; Nitta M; Takami A
Int J Hematol; 2015 Nov; 102(5):569-78. PubMed ID: 26341959
[TBL] [Abstract][Full Text] [Related]
6. SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF-α.
Pastore D; Della-Morte D; Coppola A; Capuani B; Lombardo MF; Pacifici F; Ferrelli F; Arriga R; Mammi C; Federici M; Bellia A; Di Daniele N; Tesauro M; Donadel G; Noto D; Sbraccia P; Sconocchia G; Lauro D
Cell Death Dis; 2015 Sep; 6(9):e1890. PubMed ID: 26379195
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
8. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
10. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.
Teoh PJ; Bi C; Sintosebastian C; Tay LS; Fonseca R; Chng WJ
Oncotarget; 2016 Sep; 7(38):61806-61819. PubMed ID: 27533450
[TBL] [Abstract][Full Text] [Related]
11. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H
Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454
[TBL] [Abstract][Full Text] [Related]
12. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.
Shi Y; Yang Y; Hoang B; Bardeleben C; Holmes B; Gera J; Lichtenstein A
Oncogene; 2016 Feb; 35(8):1015-24. PubMed ID: 25961916
[TBL] [Abstract][Full Text] [Related]
14. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
15. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
17. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ
Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177
[TBL] [Abstract][Full Text] [Related]
19. High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule.
Saad S; Stevens VA; Wassef L; Poronnik P; Kelly DJ; Gilbert RE; Pollock CA
Kidney Int; 2005 Sep; 68(3):985-97. PubMed ID: 16105029
[TBL] [Abstract][Full Text] [Related]
20. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
